In its latest quarterly filing, Intellia Therapeutics reported continued advancement of its pioneering in vivo CRISPR gene editing candidates, particularly lonvo-z for hereditary angioedema (HAE) and nex-z for transthyretin amyloidosis (ATTR). The company is on track to seek regulatory approval and launch lonvo-z in early 2027, supported by a robust cash position boosted by a recent $195 million equity raise. Intellia’s differentiated one-time gene editing therapies targeting root causes position it uniquely within the biotechnology landscape. However, regulatory risks, clinical uncertainties, and commercialization execution remain key challenges that will shape its trajectory.